Alicia Hart
Family · Zachary, LANPI 1750716841
Payments from drug & device makers
Across 124 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$726
- Novo Nordisk$384
- AbbVie$352
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$200
- GSK$118
- Amgen$92
- plus $359 from 11 others
What the payments were for
- Food & beverage$2,230100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 38 | $726 |
| Novo Nordisk | 23 | $384 |
| AbbVie | 19 | $352 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $200 |
| GSK | 7 | $118 |
| Amgen | 6 | $92 |
| Paratek Pharmaceuticals, Inc. | 3 | $56 |
| Boehringer Ingelheim | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Pfizer | 2 | $36 |
| AstraZeneca | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Merck | 2 | $28 |
| Abbott | 1 | $18 |
| Bayer | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
How this compares
$2,230 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 48 | $47,200 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 27 | $42,163 |
| JardianceEmpagliflozin | 38 | $41,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $36,688 |
| OzempicSemaglutide | 34 | $35,506 |
| MounjaroTirzepatide | 25 | $29,263 |
| VraylarCariprazine Hcl | 12 | $20,205 |
| TrulicityDulaglutide | 13 | $16,793 |
| FarxigaDapagliflozin Propanediol | 14 | $13,333 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $8,647 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $7,979 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $7,003 |
| Pantoprazole Sodium | 180 | $2,632 |
| Famotidine | 109 | $2,510 |
| Diclofenac Sodium | 98 | $1,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskXultophy 100-3.6, Ozempic | $384 | $77,66961 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $49 | $58,33066 claims |
| MerckJanuvia | $28 | $47,20048 claims |
| Lilly USA, LLCMounjaro, Trulicity | $726 | $46,05538 claims |
| GSKTrelegy Ellipta | $118 | $36,68844 claims |
| AbbVieVraylar, Synthroid | $352 | $21,32637 claims |
| AstraZenecaFarxiga | $34 | $13,33314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.
Other family in Zachary
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.